Activity Summary:
Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice.

From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026, this CME-accredited podcast explores how to approach these complex cases with greater clarity and confidence. Featuring expert insights and the latest clinical evidence, each episode dives into practical strategies across the continuum of gout care.

Listeners will hear discussions on advances in uricase-based therapies, selective URAT1 inhibitors, and inflammation-targeted treatments, along with key considerations around safety, sequencing, and collaborative care. Through real-world examples and focused conversations, this series equips clinicians with actionable tools to personalize treatment, address therapeutic challenges, and improve long-term outcomes for patients living with uncontrolled gout.

Activity Summary:
Managing uncontrolled gout can be challenging, especially when patients continue to flare, struggle with comorbidities, or fail to respond as expected to standard therapy. As the understanding of gout evolves beyond hyperuricemia alone, clinicians are increasingly called upon to integrate immune mechanisms, real-world evidence, and new treatment options into everyday decision-making. Staying current requires not only awareness of emerging data, but also clarity on how to apply it in complex, real-world patients.

From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026 is a CME-accredited educational program designed to help clinicians navigate these challenges with confidence. This program brings together expert perspectives, recent clinical evidence, and practical insights across the continuum of gout care. Learners will explore advances in uricase-based therapies, selective URAT1 inhibitors, and inflammation-targeted approaches, while also addressing safety, sequencing, and multidisciplinary coordination. Through focused discussion and clinically relevant examples, participants will gain actionable strategies to personalize care, overcome treatment inertia, and improve long-term management for patients living with uncontrolled gout.

Activity Summary:
Clinical care for myasthenia gravis is entering a period of meaningful progress, with growing opportunities to improve how the disease is diagnosed, assessed, and treated. Increased awareness of disease heterogeneity and the expanding use of standardized severity assessments are helping clinicians better define disease burden and guide management decisions.

In this 20-minute podcast episode, Dr. James Howard Jr. provides comprehensive coverage of key MG presentations, scientific symposia, posters, and abstracts presented at AAN 2026.

Activity Summary:
Myasthenia gravis care is advancing quickly, with new evidence shaping how clinicians approach disease assessment and treatment selection. At the same time, variability in presentation, delays in diagnosis, and uncertainty around integrating emerging therapies continue to create challenges in clinical practice. Clinicians need concise, practical education that translates evolving data into clear and actionable strategies that can be applied in real-world care.

This focused Clinical Clip from AAN 2026 features Dr James (Chip) Howard, a leading expert in myasthenia gravis, delivering a 20-minute update on the most clinically relevant advances presented in Chicago. Designed for efficiency and practical application, this program highlights how to incorporate emerging therapies into individualized treatment plans to support confident, evidence-based decision-making.

Activity Summary:
Gout remains the most common form of inflammatory arthritis in adults, yet it continues to be one of the most misunderstood and mismanaged chronic diseases in clinical practice. Despite clear treatment guidelines and a growing array of therapeutic options, a substantial proportion of patients experience persistent flares, disease progression, and comorbid complications due to clinical inertia, fragmented care, and limited provider awareness of emerging innovations. This podcast, presented by Dr. Robert Terkeltaub, seeks to modernize clinical approaches to gout, accelerate the adoption of new evidence and therapies, and ultimately improve the quality and consistency of care for a patient population long underserved by existing education.

Activity Summary:
Gout remains the most common form of inflammatory arthritis in adults, yet it continues to be one of the most misunderstood and mismanaged chronic diseases in clinical practice. Despite clear treatment guidelines and a growing array of therapeutic options, a substantial proportion of patients experience persistent flares, disease progression, and comorbid complications due to clinical inertia, fragmented care, and limited provider awareness of emerging innovations. This Lecture Library, presented by Dr. Robert Terkeltaub, seeks to modernize clinical approaches to gout, accelerate the adoption of new evidence and therapies, and ultimately improve the quality and consistency of care for a patient population long underserved by existing education.

Activity Summary:
Managing psoriasis (PsO) and psoriatic arthritis (PsA) presents multiple challenges for healthcare professionals, including staying up to date with emerging therapies, recognizing early signs of PsA, managing comorbidities, and implementing multidisciplinary care strategies. Despite advances in biologic and systemic therapies, unmet needs persist in timely diagnosis, patient education, and comprehensive disease management. Busy healthcare professionals often lack the time for in-depth study of the latest research, creating a critical need for concise, accessible educational opportunities. These unmet needs point to the necessity of practical, time-efficient programs that provide actionable insights into new treatment protocols and improve patient outcomes.

These podcast episodes are designed to provide healthcare professionals with an in-depth exploration of the most recent advances in the management of psoriasis (PsO) and psoriatic arthritis (PsA). The segments will focus on key challenges in clinical practice, including early diagnosis, personalized treatment strategies, and the integration of patient-reported outcomes. It will also address the management of associated comorbidities and the latest therapeutic developments, including biologics and small molecules.

Activity Summary:
Managing psoriasis (PsO) and psoriatic arthritis (PsA) presents multiple challenges for healthcare professionals, including staying up to date with emerging therapies, recognizing early signs of PsA, managing comorbidities, and implementing multidisciplinary care strategies. Despite advances in biologic and systemic therapies, unmet needs persist in timely diagnosis, patient education, and comprehensive disease management. Busy healthcare professionals often lack the time for in-depth study of the latest research, creating a critical need for concise, accessible educational opportunities. These unmet needs point to the necessity of practical, time-efficient programs that provide actionable insights into new treatment protocols and improve patient outcomes.

These Mini-Modules are designed to provide healthcare professionals with an in-depth exploration of the most recent advances in the management of psoriasis (PsO) and psoriatic arthritis (PsA). The segments will focus on key challenges in clinical practice, including early diagnosis, personalized treatment strategies, and the integration of patient-reported outcomes. It will also address the management of associated comorbidities and the latest therapeutic developments, including biologics and small molecules.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:
In this podcast series, Dr. Scott Canna and Dr. Alexei Grom discuss diverse mechanisms and clinical presentations in patients with suspected MAS, approaches for the timely diagnosis of MAS, and considerations for appropriate treatment and management strategies.

Activity Summary:
Talking PsA is a podcast series that highlights the very latest clinical data in Psoriatic Arthritis. This activity includes management strategies and case-based topics to help clinicians select the most appropriate treatment, as well as address the significant health burdens and complications experienced by many patients during treatment.

Activity Summary:
In this webcast archive, Dr. Scott Canna and Dr. Alexei Grom discuss diverse mechanisms and clinical presentations in patients with suspected MAS, approaches for the timely diagnosis of MAS, and considerations for appropriate treatment and management strategies.

Activity Summary:
Talking PsA is a webcast archive that highlights the very latest clinical data in Psoriatic Arthritis. Slides are developed and presented by leading Rheumatology and Dermatology experts and further reviewed and approved by the planning committee.

This activity includes case-based topics on management strategies for patients with PsA as well as clinical discussions by leading PsA experts.

Activity Summary:
Clinical Viewpoints HLH/MAS includes a curriculum that highlights the very latest clinical data in hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Slides are developed and updated throughout the year by leading HLH/MAS expert physicians. All content is reviewed and approved by the Clinical Viewpoints HLH/MAS Planning Committee.

The current initial treatment for hemophagocytic lymphohistiocytosis (HLH) and/or macrophage activation syndrome (MAS) aims to suppress the excessive activation of the immune system and treat the cytokine storm. However, contemporary HLH and MAS management is an evolving science that builds off each advance in basic/clinical research and clinical experience. This case-based slide kit discusses current controversies in the management of secondary HLH, including MAS.

Activity Summary:
The management of Psoriatic Arthritis (PsA) remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. Optimizing outcomes for PsA is dependent upon the early identifying patients, developing a personalized treatment strategy, and cohesively collaborating with a multidisciplinary team to address issues related to the challenges of diagnosis and access to appropriate therapy. Furthermore, research in PsA has evolved in recent years to reflect changes in the current disease landscape, study population, new management strategies, advanced recommendations on assessing patients’ overall disease activity and responses to treatment, healthcare providers’ and patients’ treatment expectations, and regulatory requirements. Understanding these can help guide clinical decision-making and improve outcomes for patients with PsA.

Talking PsA is an accredited AMA/ANCC/ACPE activity that highlights the very latest clinical data and is designed to optimize treatment strategies in PsA through a series of four patient case studies. The content and clinical cases were developed and presented by leading Rheumatology and Dermatology experts in PsA.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Patients seen in a typical rheumatology practice are at higher risk of PAH secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. Emerging evidence suggests that two of the most prevalent CTDs, systemic sclerosis (SSc) and systemic lupus erythematosus (SLE), should be regarded as separate diseases due to their different etiologies, prognoses, and therapeutic responses. This slide kit will present insights into the different pathophysiological processes and management of patients with SSc and SLE-PAH, as well as recommendations for routine screening, risk factors, diagnosis, management, and ongoing monitoring of patients in a rheumatology practice for PAH.

Activity Summary:
Clinical Viewpoints HLH includes a curriculum that highlights the very latest clinical data in Hemophagocytic Lymphohistiocytosis (HLH). Slides are developed and updated throughout the year by leading HLH expert physicians. The Lecture Library offers various topics that can be accessed for AMA or ANCC credit. Review the content and complete the pre- and post-tests and evaluation to receive your credit.

HLH is an aggressive and life-threatening syndrome of excessive immune activation. In persons with HLH, timely diagnosis and appropriate treatment are essential to achieving a successful outcome. This activity will utilize case-based scenarios to review the diverse clinical presentations of suspected HLH, time-efficient approaches for diagnosis, and considerations for targeted treatment and supportive management strategies. Continue to visit the Lecture Library series throughout 2022 to view updates from new publications and conference updates. All content is reviewed and approved by the Clinical Viewpoints HLH Planning Committee.

Activity Summary:
Talking PsA is a webcast archive that highlights the very latest clinical data in Psoriatic Arthritis. Slides are developed and presented by leading Rheumatology and Dermatology experts and further reviewed and approved by the planning committee.

This activity includes case-based topics on management strategies for patients with PsA as well as clinical discussions by leading PsA experts.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Patients seen in a typical rheumatology practice are at higher risk of PAH secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This lecture will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH.

Activity Summary:
The Simply Speaking Rheumatoid Arthritis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Effective strategies for rheumatoid arthritis (RA) continue to evolve; however, there are no drugs that are universally effective for all patients. Management approaches for many clinical scenarios are not specifically/adequately addressed by current treatment guidelines, necessitating consideration of the most recent clinical trial data. Awareness of advances in RA knowledge base place healthcare professionals at the forefront of RA care. This activity will explain how recent study results in RA apply to clinical practice; discuss significant developments and strategies in RA pathogenesis, measurement, and therapy; and discuss results from key clinical studies on existing and investigational RA agents.

Activity Summary:
Effective strategies for rheumatoid arthritis (RA) continue to evolve and clinicians are often challenged when presented with clinical scenarios not adequately addressed by current treatment guidelines. Many times treatment decisions necessitate consideration of the most recent clinical trial data.

These educational Clinical Clips will highlight important advances in the medical management of patients with RA based on data presented at ACR Convergence 2020 through a series of three ‘what you need to know in 5-minutes’ videos.

Activity Summary:
The Simply Speaking Rheumatoid Arthritis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

An array of targeted biologic therapies and new targeted oral small molecule agents have been approved to treat rheumatoid arthritis (RA). Many clinical scenarios necessitate collaborative decision-making to understand the appropriate role of existing and new treatments in the care for patients with RA. This activity will use a case-based approach to discuss clinical considerations impacting individualized therapy for patients with RA.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
The Simply Speaking Rheumatoid Arthritis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Prompt initiation of DMARD therapy results in higher rates of remission or low disease activity in patients with rheumatoid arthritis (RA). Despite significantly improved outcomes in RA, there is no cure—underscoring the need for individualized therapy, development of new agents, and approaches to prevent/cure RA. This activity will discuss new and emerging treatments for RA, data on when to initiate treatment as it relates to RA prevention, and clinical considerations impacting individualized therapy for patients with RA.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.